Pituitary hypoplasia and growth hormone deficiency in a patient with Coffin-Siris syndrome and severe short stature: case report and literature review

Stefana Catalina Bilha, Laura Teodoriu, Cristian Velicescu, Lavinia Caba


Coffin-Siris syndrome (CSS) is a rare genetic disorder caused by the haploinsufficiency of one of the various genes that are part of the Brahma/BRG1-associated factor (BAF) complex. The BAF complex is one of the chromatin remodeling complexes, involved in embryonic and neural development, and various gene mutations are associated with cognitive impairment. CSS has a highly variable genotype and phenotype expression, thus lacking standardized criteria for diagnosis. It is generally accepted to associate 5th digit/nail hypoplasia, intellectual disability (ID)/developmental delay and specific coarse facial features. CSS patients usually display miscellaneous cardiac, genitourinary and central nervous system (CNS) anomalies. Many patients also associate intrauterine growth restriction, failure to thrive and short stature, with several cases demonstrating growth hormone deficiency (GHD). We report the case of a 4-year-old girl with severe short stature (-3.2 standard deviations) due to pituitary hypoplasia and GHD that associated hypoplastic distal phalanx of the 5th digit in the hands and feet, severe ID, coarse facial features (bushy eyebrows, bulbous nose, flat nasal bridge, dental anomalies, thick lips, dental anomalies, bilateral epicanthal fold) and CNS anomalies (agenesis of the corpus callosum and bilateral hippocampal atrophy), thus meeting clinical criteria for the diagnosis of CSS. Karyotype was 46,XX. The patient was started on GH replacement therapy, with favorable outcomes. Current practical knowledge regarding CSS diagnosis and management from the endocrinological point of view is also reviewed.


Coffin-Siris syndrome; BAF remodeling complex; short stature; GH deficiency; CNS malformations

Full Text:



Vasko A, Drivas TG, Schrier Vergano SA. Genotype-phenotype correlations in 208 individuals with coffin-siris syndrome. Genes (Basel). 2021;12(6):937

Lopez AJ, Wood MA. Role of nucleosome remodeling in neurodevelopmental and intellectual disability disorders. Front Behav Neurosci. 2015;9:100

Coffin GS, Siris E. Mental retardation with absent fifth fingernail and terminal phalanx. Am J Dis Child. 1970; 119:433–439.

Fleck BJ, Pandya A, Vanner L, Kerkering K, Bodurtha J. Coffin‐Siris syndrome: Review and presentation of new cases from a questionnaire study. Am J Med Genet. 2001; 99(1):1-7

Vergano SA, Sluijs PJ van der, Santen G. ARID1B-Related Disorder. 2019. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle: University of Washington, Seattle: 1993-2022.

Vasko A, Schrier Vergano SA. Language impairments in individuals with Coffin-Siris syndrome. Front Neurosci. 2022; 15: 802583.

Schrier SA, Bodurtha JN, Burton B, et al. The Coffin-Siris syndrome: a proposed diagnostic approach and assessment of 15 overlapping cases. Am J Med Genet A. 2012; 158A:1865–1876.

Baban A, Moresco L, Divizia MT, et al. Pituitary hypoplasia and growth hormone deficiency in Coffin-Siris syndrome. Am J Med Genet A. 2008; 146A:384–388.

Pascanu I, Pop R, Barbu CG, et al. Endocrine care development of synthetic growth charts for Romanian population. Acta Endocrinol. 2016; XII:309–318.

World Health Organisation. WHO Child growth standards: Height-for-age girls 2 to 5 years (percentiles).[https://cdn.who.int/media/docs/default-source/child-growth/child-growth-standards/indicators/length-height-for-age/hfa-girls-2-5-percentiles.pdf?sfvrsn=adc3b954_7]

Yau M, Rapaport R. Growth hormone stimulation testing: to test or not to test? That is one of the questions. Front Endocrinol (Lausanne). 2022; 0:1099.

Caputo M, Pigni S, Agosti E, et al. Regulation of GH and GH signaling by nutrients. Cells. 2021; 10(6):1376

Hawkes CP, Grimberg A, Dzata VE, De Leon DD. Adding glucagon stimulated GH testing to the diagnostic fast increases the detection of GH sufficient children. Horm Res Paediatr. 2016; 85(4):265-272.

Seaver LH, Irons M. ACMG practice guideline: Genetic evaluation of short stature. Genet Med. 2009;11:465.

Preda C, Ungureanu MC, Leustean L, Cristea C, Vulpoi C. Ethical issues related to the use of human growth hormone in idiopathic short stature. Revista Romana de Bioetica 2013; 11(4): 31-37.

Dauber A, Rosenfeld RG, Hirschhorn JN. Clinical Review: Genetic evaluation of short stature. J Clin Endocrinol Metab. 2014; 99:3080.

Alfert A, Moreno N, Kerl K. The BAF complex in development and disease. Epigenetics Chromatin 2019. 2019; 12:1–15.

Miyake N, Tsurusaki Y, Matsumoto N. Numerous BAF complex genes are mutated in Coffin-Siris syndrome. Am J Med Genet C Semin Med Genet. 2014; 166C:257–261.

Sim JCH, White SM, Lockhart PJ. ARID1B-mediated disorders: Mutations and possible mechanisms. Intractable Rare Dis Res. 2015;4:17–23

Yu Y, Yao RE, Wang L, et al. De novo mutations in ARID1B associated with both syndromic and non-syndromic short stature. BMC Genomics. 2015; 16:1–10.

Wright CF, Fitzgerald TW, Jones WD, et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet (London, England). 2015; 385:1305–1314.

Hoyer J, Ekici AB, Endele S, et al. Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability. Am J Hum Genet. 2012; 90(3):565-572.

van der Sluijs PJ, Jansen S, Vergano SA, et al. The ARID1B spectrum in 143 patients: from nonsyndromic intellectual disability to Coffin–Siris syndrome. Genet Med. 2019; 21(6):1295-1307.

Bögershausen N, Wollnik B. Mutational Landscapes and phenotypic spectrum of SWI/SNF-related intellectual disability disorders. Front Mol Neurosci. 2018; 11:252.

Machol K, Rousseau J, Ehresmann S, et al. Expanding the spectrum of BAF-related disorders: de novo variants in SMARCC2 cause a syndrome with intellectual disability and developmental delay. Am J Hum Genet. 2019; 104(1):164–178.

Zawerton A, Yao B, Yeager JP, et al. De novo SOX4 variants cause a neurodevelopmental disease associated with mild dysmorphism. Am J Hum Genet. 2019; 104(2):246-259.

Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum disorders: an overview. Neuropsychol Rev. 2011; 21(2):73-80.

Vergano SS, Deardorff MA. Clinical features, diagnostic criteria, and management of Coffin-Siris syndrome. Am J Med Genet Part C Semin Med Genet. 2014; 166:252–256.

McCague EA, Lamichhane R, Holt N, Schrier Vergano SA. Growth charts for individuals with Coffin-Siris syndrome. Am J Med Genet Part A. 2020; 182:2253–2262.

DOI: http://dx.doi.org/10.22551/2022.36.0903.10216

Copyright (c) 2022 Stefana Catalina Bilha, Laura Teodoriu, Cristian Velicescu, Lavinia Caba

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975